NASDAQ: BIIB - Biogen

Rentabilität für sechs Monate: -28.12%
Dividendenrendite: 0.00%
Sektor: Healthcare

Nachricht

FDA chief calls for investigation into Biogen Alzheimer's drug approval process

18 november 18:30 FDA chief calls for investigation into Biogen Alzheimer's drug approval process

FDA to decide on full approval of Alzheimer's treatment Leqembi in early July

18 november 18:12 FDA to decide on full approval of Alzheimer's treatment Leqembi in early July

FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says

18 november 18:10 FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says

Biogen picks new CEO, veteran pharmaceutical leader Christopher Viehbacher

18 november 18:09 Biogen picks new CEO, veteran pharmaceutical leader Christopher Viehbacher

FDA trims use of contentious Alzheimer's drug amid backlash

18 november 17:54 FDA trims use of contentious Alzheimer's drug amid backlash

Biogen investigates death of patient who took Alzheimer’s drug

18 november 17:44 Biogen investigates death of patient who took Alzheimer’s drug

Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drug

18 november 17:28 Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drug

iPhones may soon detect depression, autism, and cognitive decline: report

18 november 17:00 iPhones may soon detect depression, autism, and cognitive decline: report

Panel says Biogen's Aduhelm Alzheimer's drug shows no benefit

18 november 16:54 Panel says Biogen's Aduhelm Alzheimer's drug shows no benefit

Biden pushes Congress to allow Medicare to negotiate drug prices

18 november 16:20 Biden pushes Congress to allow Medicare to negotiate drug prices

Aktie

Werkzeuge

Gemeinschaft

Kontakte

2025 © Investing Port
Kontakte | Werbung
Die Verwendung von porti.ru-Materialien ist nur zulässig, wenn ein aktiver indizierter Link zur Quelle vorhanden ist.